全文获取类型
收费全文 | 1429149篇 |
免费 | 99744篇 |
国内免费 | 3301篇 |
专业分类
耳鼻咽喉 | 20744篇 |
儿科学 | 42633篇 |
妇产科学 | 40275篇 |
基础医学 | 198560篇 |
口腔科学 | 41581篇 |
临床医学 | 122441篇 |
内科学 | 280557篇 |
皮肤病学 | 31433篇 |
神经病学 | 115471篇 |
特种医学 | 57227篇 |
外国民族医学 | 451篇 |
外科学 | 223239篇 |
综合类 | 32073篇 |
现状与发展 | 6篇 |
一般理论 | 565篇 |
预防医学 | 100775篇 |
眼科学 | 33250篇 |
药学 | 106098篇 |
4篇 | |
中国医学 | 3087篇 |
肿瘤学 | 81724篇 |
出版年
2018年 | 14038篇 |
2016年 | 12369篇 |
2015年 | 13947篇 |
2014年 | 19820篇 |
2013年 | 29561篇 |
2012年 | 39857篇 |
2011年 | 42078篇 |
2010年 | 24870篇 |
2009年 | 23918篇 |
2008年 | 40057篇 |
2007年 | 43382篇 |
2006年 | 43772篇 |
2005年 | 42185篇 |
2004年 | 41149篇 |
2003年 | 39469篇 |
2002年 | 38740篇 |
2001年 | 64464篇 |
2000年 | 65933篇 |
1999年 | 56245篇 |
1998年 | 15756篇 |
1997年 | 14308篇 |
1996年 | 13675篇 |
1995年 | 12972篇 |
1994年 | 12125篇 |
1992年 | 43349篇 |
1991年 | 41785篇 |
1990年 | 40977篇 |
1989年 | 39881篇 |
1988年 | 37295篇 |
1987年 | 36738篇 |
1986年 | 35202篇 |
1985年 | 33428篇 |
1984年 | 25159篇 |
1983年 | 21329篇 |
1982年 | 12980篇 |
1981年 | 11843篇 |
1979年 | 24057篇 |
1978年 | 17221篇 |
1977年 | 14946篇 |
1976年 | 13490篇 |
1975年 | 15349篇 |
1974年 | 18175篇 |
1973年 | 17655篇 |
1972年 | 16888篇 |
1971年 | 15784篇 |
1970年 | 14976篇 |
1969年 | 14408篇 |
1968年 | 13521篇 |
1967年 | 12049篇 |
1966年 | 11298篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Zhenzhen Zhang Mark Garzotto Tomasz M. Beer Philippe Thuillier Stephen Lieberman Motomi Mori 《Nutrition and cancer》2016,68(8):1309-1319
Animal and human studies suggest fish oil and green tea may have protective effect on prostate cancer. Fatty acid synthase (FAS) has been hypothesized to be linked to chemoprotective effects of both compounds. This study evaluated the independent and joint effects of fish oil (FO) and green tea supplement (epigallocatechin-3-gallate, EGCG) on FAS and Ki-67 levels in prostate tissue. Through a double-blinded, randomized controlled trial with 2 × 2 factorial design, 89 men scheduled for repeat prostate biopsy following an initial negative prostate biopsy were randomized into either FO alone (1.9 g DHA + EPA/day), EGCG alone (600 mg/day), a combination of FO and EGCG, or placebo. We used linear mixed-effects models to test the differences of prostate tissue FAS and Ki-67 by immunohistochemistry between pre- and post-intervention within each group, as well as between treatment groups. Results did not show significant difference among treatment groups in pre-to-post-intervention changes of FAS (P = 0.69) or Ki-67 (P = 0.26). Comparing placebo group with any of the treatment groups, we did not find significant difference in FAS or Ki-67 changes (all P > 0.05). Results indicate FO or EGCG supplementation for a short duration may not be sufficient to produce biologically meaningful changes in FAS or Ki-67 levels in prostate tissue. 相似文献
4.
Improvement in Tricuspid Annular Plane Systolic Excursion with Pulmonary Hypertension Therapy in Pediatric Patients 下载免费PDF全文
5.
6.
7.
8.
9.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
10.